Company: JUNS
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001641172-25-010990
Chunk: 62

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-05-15
Form: 10-Q
Item: Item 2
Chunk 62
---
The following
discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited
condensed financial statements and related notes included in this Quarterly Report on Form 10-Q and the audited financial
information and related notes included in our Annual Report on Form 10-K for fiscal 2024, which was filed with the Securities and Exchange
Commission, or the SEC, on March 28, 2025, or the Annual Report.

Special Note Regarding Forward-Looking Statements

All statements other than
statements of historical fact included in this Quarterly Report on Form 10-Q, including, without limitation, statements under “Management’s
Discussion and Analysis of Financial Condition and Results of Operations” regarding the Company’s financial position, business
strategy and the plans and objectives of management for future operations, are forward-looking statements. When used in this Quarterly
Report on Form 10-Q, words such as “anticipate,” “believe,” “estimate,” “expect,” “intend”
and similar expressions, as they relate to us or the Company’s management, identify forward-looking statements. Such forward-looking
statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, the Company’s
management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors
detailed in our filings with the SEC.

The following discussion
and analysis of our financial condition and results of operations should be read in conjunction with the financial statements and the
notes thereto contained elsewhere in this Quarterly Report on Form 10-Q. Certain information contained in the discussion and analysis
set forth below includes forward-looking statements that involve risks and uncertainties. Unless the context otherwise requires, “JNS,”
“we,” “us,” “our,” or the “Company” refers to Jupiter Neurosciences, Inc.

Business Overview

We are a clinical stage research and development
company. We have developed a unique resveratrol platform product primarily targeting treatment of neuro-inflammation. Our platform product,
JOTROL, an enhanced oral formulation of resveratrol, has many potential indications of use for rare diseases. In the larger disease areas,
we are primarily targeting Parkinson’s Disease and Mild Cognitive Impairment/early Alzheimer’s disease.

In December 2024, we received gross proceeds
of $11 million, before deduction of underwriting discounts and other related expenses, in a registered public offering
(“Public Offering”)